United States Patent 9,187,749: Claim-By-Claim Validity Pressure Points and US Landscape

US 9,187,749 claims prophylactic treatment of hereditary angioedema (HAE) using a short modified oligonucleotide (12 to 30 linked nucleosides) that is at least 90% complementary to “Factor 12” nucleic acid, with dependent claim buildouts covering human targeting, oligonucleotide chemistry, and combination with standard HAE drugs.

What does the patent actually claim, in operational terms?

The independent claim 1 is a method claim. It is not limited to a specific dosing regimen, route is only later limited in dependent claims, and “prophylactically treating” is broad as a functional purpose. The core enforceable elements are:

Indication and population: prophylaxis for an animal “identified as having HAE.”
Active: “a compound comprising a modified oligonucleotide.”
Size: 12 to 30 linked nucleosides.
Target relationship: modified oligonucleotide is at least 90% complementary to a Factor 12 nucleic acid.
Therapeutic intent: “therapeutically effective amount” for prophylactic HAE treatment.

Dependent claims narrow along four axes: therapeutic effect wording, specific target sequences, oligonucleotide chemistry, and combination therapy.

Claim matrix (what each claim adds)

Claim	Additional limitation vs. claim 1	Scope impact
2	Prevents or ameliorates edema	Narrows to edema effect; still functional
3	Prevents or ameliorates vascular permeability	Adds vascular mechanism wording
4	Prevents or ameliorates vascular leakage	Adds alternative wording of mechanism
5	Prevents or ameliorates inflammation	Adds broader inflammatory outcome
6	Animal is human	Locks to human use
7	Factor 12 nucleic acid is human	Locks target species
8	Human Factor 12 nucleic acid is one of SEQ ID NOs 1-7 or complement of SEQ ID NO 8	Narrows to specific sequence set
9	Oligonucleotide is 100% complementary to that human Factor 12 nucleic acid	Tightens matching stringency
10	Modified oligonucleotide is single-stranded	Restricts duplex-forming designs
11	Modified oligonucleotide comprises at least one modified internucleoside linkage	Chemistry constraint
12	Linkage is phosphorothioate	Major implementation constraint (common in antisense)
13	At least one nucleoside has a modified sugar	Chemistry constraint
14	Sugar is bicyclic	Narrows to specific sugar class
15	Sugar includes 4’-CH(CH3)-O-2’ bridge	Hardens to a specific bicyclic architecture
16	Sugar includes 2’-O-methoxyethyl group	Hardens further
17	At least one nucleobase is modified	Chemistry constraint
18	Modified base is 5-methylcytosine	Hardens further
19	Co-administer with listed HAE drugs (C1-INH recombinant; CINRYZE; BERINERT; KALBITOR; icatibant; ecallantide; attenuated androgens; anabolic steroids; antifibrinolytics like tranexamic acid; etc.)	Expands real-world combinations but also invites prior art combinations
20	Administering is parenteral	Route constraint
21	Route is subcutaneous or intravenous	Narrows route options
22	Compound comprises a conjugate	Additional formulation/construct restriction

Critical observation: the claim structure is “antisense-by-complementarity” with broad functional prophylaxis

The claim is primarily defined by hybridization/sequence complementarity (≥90% in claim 1, 100% in claim 9) and by a short length window (12 to 30), then it shifts to standard nucleic-acid chemistry terms (phosphorothioate, modified sugars/bases, single-stranded) that are widely used across antisense oligos.

That creates two high-leverage validity and design-around issues:

Prior art overlap risk: short antisense oligonucleotides targeting disease-relevant nucleic acids with common backbones and sugars are heavily populated in patents.
Enforceability vs. breadth tension: functional prophylactic outcome claims (edema/vascular permeability/leakage/inflammation) can raise proof and enablement pressure if not supported with clear mechanistic and empirical data for the full breadth of “12 to 30” and “≥90% complementary.”

What is the main novelty hook, and where will it face the strongest attack?

Likely novelty hook: Factor 12 (contact system) targeting with modified oligo length and complementarity constraints

HAE pathophysiology commonly involves bradykinin and the kallikrein-kinin system, with factor XIIa implicated upstream. The independent claim ties HAE prophylaxis to an oligo that binds Factor 12 nucleic acid.

Highest-risk vulnerability: broad complementarity + broad “modified oligonucleotide” class

From a patentability perspective, the breadth is significant:

12–30 nucleosides: a wide antisense window used in many established programs.
≥90% complementarity: allows many near-match designs. In practice, depending on mismatch positions, many antisense candidates could qualify.
“Modified oligonucleotide” is not confined to a single chemistry in claim 1 (chemistry is only later narrowed in dependent claims).

This is the kind of claim set that is vulnerable to:

Anticipation (one document discloses the method using an oligo that meets the same sequence-binding parameters and prophylactic effect).
Obviousness (multiple documents independently disclose: (i) HAE prophylaxis logic via reducing Factor XII activity/expression; (ii) antisense oligos with the claimed size/complementarity; (iii) use of standard modifications like phosphorothioate and bicyclic sugars).
Lack of enablement/insufficient written description pressure (if the patent does not provide a teaching that covers the full breadth of 12–30 and ≥90% complementarity for Factor 12 across sequence space).

Practical enforceability vulnerability: dependent chemistry is very specific

Claims 11–18 progressively narrow to specific chemical motifs:

phosphorothioate linkage
bicyclic sugar with 4’-CH(CH3)-O-2’ bridge
2’-O-methoxyethyl group
5-methylcytosine

This specificity can help validity (if it is truly unusual in the cited art). But it also means competitors can aim for non-infringing chemistries if claim 1 is broad enough to cover them but claim 1 lacks those chemistry limitations (meaning claim 1 could still be asserted).

How strong is the claim set against typical US anticipation and obviousness theories?

1) Anticipation likelihood: medium for claim 1, low for dependent “chemistry+base+sugar” claims

Claim 1: Anticipation requires a single prior art reference to disclose:
- HAE prophylaxis,
- using a modified oligonucleotide,
- 12–30 nucleosides,
- at least 90% complementary to Factor XII nucleic acid,
- administered prophylactically. This is a high bar for one document.
Claim 8/9 (sequence-locked): anticipation requires the specific SEQ ID NO-based target set and 100% complementarity designs. That is more likely to fail unless the same sequences are already disclosed elsewhere for Factor XII.
Claims 14–18 (chemistry locked): anticipation is less likely unless the exact chemical architecture and base modification appear in a prior art oligo specific to Factor XII or a directly corresponding disclosure.

2) Obviousness likelihood: high across the board

Even if no single reference anticipates, US 102/103 frameworks can piece together:

known role of Factor XII/contact system in HAE or bradykinin generation,
known use of antisense/siRNA/oligonucleotides to downregulate target nucleic acids,
common oligonucleotide length windows,
common backbone and sugar modifications (phosphorothioate, bicyclic sugars, 2’-O-methoxyethyl),
common combination paradigms in HAE (C1-INH products, bradykinin pathway antagonists, and adjuncts).

Claim 19 listing explicit co-admin drugs can become an obviousness amplifier if prior art already reports combination use or if these drugs were standard of care and the oligonucleotide is framed as an adjunct.

What design-arounds are suggested by the claim language?

Competitors usually target either (a) the complementarity/length rules, (b) the backbone/sugar constraints, or (c) the prophylaxis framing and outcome categories.

Complementarity and sequence-stringency levers

Avoid being 12 to 30 nucleosides (claim 1).
Avoid ≥90% complementarity to the Factor 12 nucleic acid (claim 1).
Avoid 100% complementarity to the specific SEQ ID NO set (claims 8–9).

Structural/formulation levers

Use non–single-stranded designs if targeting claim 10.
Use backbones that are not phosphorothioate if targeting claim 12.
Use sugar chemistries different from the bicyclic 4’-CH(CH3)-O-2’ bridge + 2’-O-methoxyethyl combination if targeting claims 14–16.
Use nucleobases different from 5-methylcytosine if targeting claims 17–18.
Avoid a “conjugate” construct if targeting claim 22.

Functional/outcome framing

Claims 2–5 are functional: “prevents or ameliorates” edema, vascular permeability, vascular leakage, inflammation. Avoiding claim 2–5 is relatively easier than avoiding claim 1, because claim 1 already recites prophylactic HAE treatment. That said, if an alternative therapy is framed as therapeutic (on-demand) rather than prophylactic, it can reduce alignment to the claim’s intended use.

Where does the patent landscape risk cluster?

Without the full prosecution history and cited references, the cleanest landscape read is structural: this claim set sits in a crowded technical zone:

HAE therapeutics are dominated by C1-INH replacement (plasma-derived and recombinant), bradykinin receptor antagonists (icatibant), kallikrein inhibitors (ecallantide), and androgen-based prophylaxis.
Contact system targets (including factor XII) have been explored with nucleic-acid and protein approaches.
Antisense/modified oligonucleotide chemistries using phosphorothioate linkages, methylated bases, and bicyclic sugars are established toolsets in multiple therapeutic domains.

So the landscape risk is not that the idea of nucleic-acid intervention in HAE is novel. The risk is that the patent’s particular claim form may be difficult to distinguish from prior antisense-oligo targeting practice applied to Factor XII nucleic acid.

How does the combination claim (claim 19) affect freedom-to-operate?

Claim 19 does not require that the oligonucleotide is the only active; it allows co-administration with a group of standard HAE drugs.

Freedom-to-operate sensitivity:

If a competitor uses an approved HAE drug plus an oligonucleotide that meets claim 1 (sequence and size) they risk falling within a method claim even when the oligonucleotide is the differentiator.
If the oligonucleotide is outside the complementarity window or has different nucleoside chemistry, claim 19 becomes less threatening.

Claim 19 can also complicate invalidity strategy: if prior art already combines contact-system targeting with bradykinin pathway agents, the claim’s combination list may not add patentable distinction.

What is the likely claim construction behavior in US litigation?

US courts will construe:

“modified oligonucleotide” broadly enough to cover any nucleoside chemical modifications (unless the specification limits it for claim 1).
“linked nucleosides” as covalently connected oligo units; spacing and internucleotide linkage specifics are likely only required by dependent claims.
“at least 90% complementary” by standard complementarity metrics, typically counting mismatches within the alignment window.
“Factor 12 nucleic acid” by context: likely human F12 mRNA or DNA target sequences. Dependent claim 7 confirms the “human Factor 12 nucleic acid” scenario.

The most litigation-relevant construction issue is the complementarity threshold. If the prosecution record or specification uses particular alignment rules (gap handling, alignment start/end, mismatch counting), those facts can control.

So what is the practical patent strength profile?

Strength where the patent is likely to hold

Against close copies that use:
- the same Factor XII target sequence set (SEQ ID NOs 1–8 complement rule),
- 12–30 length,
- single-stranded oligo,
- phosphorothioate internucleosides,
- bicyclic sugar with the specified bridge and 2’-O-methoxyethyl,
- 5-methylcytosine.
For enforcement around “adjunctive” use with standard HAE drugs if the core oligonucleotide matches claim 1.

Weakness where the patent is likely to lose ground

If prior art shows Factor XII nucleic-acid targeting with modified oligos in HAE contexts, claim 1 can be attacked through 102/103 using combination of disclosures.
If the specification supports only narrow sequence chemistries but claim 1 covers a broad set of 12–30 and ≥90% complementarity, the patent faces written description and enablement pressure tied to breadth.

Key Takeaways

US 9,187,749 is a method-of-use claim centered on modified oligonucleotides (12–30 nucleosides) that are ≥90% complementary to Factor 12 nucleic acid, with dependent claims locking in human target sequences and a highly specific oligo chemistry package (phosphorothioate, bicyclic sugar architecture, 2’-O-methoxyethyl, and 5-methylcytosine).
The enforcement core is claim 1 (complementarity + length + prophylaxis). Dependent claims 8–18 tighten to the point where validity may improve but competitor design-around becomes easier.
Combination claim 19 expands real-world use cases by allowing co-administration with standard HAE drugs, which can increase obviousness risk and complicate freedom-to-operate if the oligo otherwise falls within claim 1.
Landscape risk is concentrated in the overlap of (i) contact-system targeting for HAE, (ii) antisense/modified oligo use patterns, and (iii) common oligo chemistries already embedded across nucleic-acid therapeutics.

FAQs

1) What is the decisive claim limitation for infringement risk?

The decisive limitation is the modified oligonucleotide meeting the sequence/length criteria in claim 1: 12–30 linked nucleosides and at least 90% complementarity to Factor 12 nucleic acid, used to prophylactically treat HAE.

2) Which dependent claims most constrain the oligo chemistry?

Claims 11–18 constrain internucleoside linkage (claim 12 phosphorothioate), sugar (claims 14–16 bicyclic sugar with the specified 4’-CH(CH3)-O-2’ bridge and 2’-O-methoxyethyl), and nucleobase (claims 17–18 5-methylcytosine).

3) Does the patent require a specific dosing schedule?

No. The claims use “therapeutically effective amount” and route limitations only appear in dependent claims (parenteral; subcutaneous or intravenous).

4) Can a competitor avoid infringement by changing route?

Route limitations (claims 20–21) are dependent. Claim 1 itself is not restricted to parenteral use, so route alone is not a complete design-around.

5) How does the combination claim affect freedom-to-operate?

Claim 19 allows co-administration with several standard HAE therapies. If an at-risk oligonucleotide matches claim 1, combining it with listed standard drugs can still land within the method claim.

References

[1] United States Patent 9,187,749. Claims as provided in prompt.

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Takeda Pharmaceuticals U.s.a., Inc.	CINRYZE	c1 esterase inhibitor (human)	For Injection	125267	October 10, 2008	9,187,749	2032-06-08
Takeda Pharmaceuticals U.s.a., Inc.	KALBITOR	ecallantide	Injection	125277	December 01, 2009	9,187,749	2032-06-08
Csl Behring Gmbh	BERINERT	c1 esterase inhibitor (human)	For Injection	125287	October 09, 2009	9,187,749	2032-06-08
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Patent: 9,187,749

Summary for Patent: 9,187,749